GlassScriptPhysician profile
Jennifer Shea Moses
NPI 1063515807
$8,019.42
in general payments reported to CMS, 2019-2025
47 companies · $777 in 2025
The $777 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $863 · 2021: $1,838 · 2022: $1,434 · 2023: $1,216 · 2024: $897 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.11 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,205.24 | 2019-2025 | |
| Astellas Pharma US INC | $905.54 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $748.80 | 2020-2025 | Slynd |
| Pfizer INC. | $451.83 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $359.87 | 2019-2025 | Trintellix |
| Organon LLC | $322.02 | 2021-2025 | Nexplanon, Jada System |
| Mayne Pharma Commercial LLC | $261.34 | 2021-2025 | |
| Novo Nordisk INC | $249.13 | 2019-2025 | Wegovy, Saxenda |
| Therapeuticsmd, INC. | $201.38 | 2019-2022 | |
| Gynesonics, INC. | $175.00 | 2021 | |
| Hologic Sales and Service, LLC | $168.03 | 2019-2025 | Novasure, Myosure Tissue Removal Device |
| Amgen INC. | $144.42 | 2019-2023 | Prolia, Evenity |
| Biohaven Pharmaceuticals, INC. | $138.77 | 2020-2021 | |
| Myriad Women'S Health, INC. | $132.07 | 2023 | Myrisk |
| Biohaven Pharmaceutical Holding Company LTD. | $125.31 | 2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $122.72 | 2024-2025 | Myfembree, Gemtesa |
| Allergan, INC. | $119.37 | 2019-2020 | |
| Lilly USA, LLC | $113.55 | 2019-2025 | Zepbound |
| Daiichi Sankyo INC. | $96.39 | 2020-2022 | |
| Medtronic, INC. | $91.67 | 2023 | Sonicision |
| Shield Therapeutics INC | $67.89 | 2022-2025 | |
| Eisai INC. | $67.21 | 2020-2021 | |
| Evofem Biosciences, INC. | $65.88 | 2021-2025 | Phexxi, Solosec, Phexx |
| Lupin INC. | $63.35 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.06 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $48.89 | 2019-2021 | |
| Avion Pharmaceuticals | $47.10 | 2020-2023 | Balcoltra |
| Urovant Sciences INC | $41.52 | 2021-2022 | |
| Davol INC. | $40.53 | 2022 | |
| Zyla Life Sciences, INC. | $35.76 | 2020 | |
| Becton, Dickinson and Company | $33.63 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $32.55 | 2021-2024 | Onzetra Xsail, Contrave |
| Coopersurgical, INC. | $29.58 | 2019 | |
| Radius Health, INC. | $25.72 | 2020-2021 | |
| Myovant Sciences INC. | $25.18 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $25.09 | 2019 | |
| Solventum Corporation | $24.80 | 2025 | Prevena |
| Amag Pharmaceuticals, INC. | $24.12 | 2019-2020 | |
| Fisher Scientific Company L.L.C. | $21.68 | 2024 | Procalcitonin |
| Dexcom, INC. | $17.63 | 2025 | Dexcom G6 Transmitter |
| Minerva Surgical, INC | $17.24 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $16.00 | 2019 | |
| Exact Sciences Corporation | $14.93 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $14.91 | 2019 | |
| Boston Scientific Corporation | $13.61 | 2019 | |
| Smith+Nephew, INC. | $12.10 | 2022 | |
| Allegis Pharmaceuticals, LLC | $11.01 | 2023 | Urimar-T Caps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.